The MAGPI Survey: Effects of Spiral Arms on Different Tracers of the Interstellar Medium and Stellar Populations at z~0.3

Spiral structures are important drivers of the secular evolution of disc galaxies, however, the origin of spiral arms and their effects on the development of galaxies remain mysterious. In this work, we present two three-armed spiral galaxies at z~0.3 in the Middle Age Galaxy Properties with Integral Field Spectroscopy (MAGPI) survey. Taking advantage of the high spatial resolution (~0.6'') of the Multi-Unit Spectroscopic Unit (MUSE), we investigate the two-dimensional distributions of different spectral parameters: Halpha, gas-phase metallicity, and D4000. We notice significant offsets in Halpha (~0.2 dex) as well as gas-phase metallicities (~0.05 dex) among the spiral arms, downstream and upstream of MAGPI1202197197 (SG1202). This observational signature suggests the spiral structure in SG1202 is consistent with arising from density wave theory. No azimuthal variation in Halpha or gas-phase metallicities is observed in MAGPI1204198199 (SG1204), which can be attributed to the tighter spiral arms in SG1204 than SG1202, coming with stronger mixing effects in the disc. The absence of azimuthal D4000 variation in both galaxies suggests the stars at different ages are well-mixed between the spiral arms and distributed around the disc regions. The different azimuthal distributions in Halpha and D4000 highlight the importance of time scales traced by various spectral parameters when studying 2D distributions in spiral galaxies. This work demonstrates the feasibility of constraining spiral structures by tracing interstellar medium (ISM) and stellar population at z~0.3, with a plan to expand the study to the full MAGPI survey.Comment: 15 pages, 11 figures, 2 tables, accepted for publication in MNRA

In Children With Nonalcoholic Fatty Liver Disease, Cysteamine Bitartrate Delayed Release Improves Liver Enzymes but Does Not Reduce Disease Activity Scores

Background & aimsNo treatment for nonalcoholic fatty liver disease (NAFLD) has been approved by regulatory agencies. We performed a randomized controlled trial to determine whether 52 weeks of cysteamine bitartrate delayed release (CBDR) reduces the severity of liver disease in children with NAFLD.MethodsWe performed a double-masked trial of 169 children with NAFLD activity scores of 4 or higher at 10 centers. From June 2012 to January 2014, the patients were assigned randomly to receive CBDR or placebo twice daily (300 mg for patients weighing ≤65 kg, 375 mg for patients weighing >65 to 80 kg, and 450 mg for patients weighing >80 kg) for 52 weeks. The primary outcome from the intention-to-treat analysis was improvement in liver histology over 52 weeks, defined as a decrease in the NAFLD activity score of 2 points or more without worsening fibrosis; patients without biopsy specimens from week 52 (17 in the CBDR group and 6 in the placebo group) were considered nonresponders. We calculated the relative risks (RR) of improvement using a stratified Cochran-Mantel-Haenszel analysis.ResultsThere was no significant difference between groups in the primary outcome (28% of children in the CBDR group vs 22% in the placebo group; RR, 1.3; 95% confidence interval [CI], 0.8-2.1; P = .34). However, children receiving CBDR had significant changes in prespecified secondary outcomes: reduced mean levels of alanine aminotransferase (reduction, 53 ± 88 U/L vs 8 ± 77 U/L in the placebo group; P = .02) and aspartate aminotransferase (reduction, 31 ± 52 vs 4 ± 36 U/L in the placebo group; P = .008), and a larger proportion had reduced lobular inflammation (36% in the CBDR group vs 21% in the placebo group; RR, 1.8; 95% CI, 1.1-2.9; P = .03). In a post hoc analysis of children weighing 65 kg or less, those taking CBDR had a 4-fold better chance of histologic improvement (observed in 50% of children in the CBDR group vs 13% in the placebo group; RR, 4.0; 95% CI, 1.3-12.3; P = .005).ConclusionsIn a randomized trial, we found that 1 year of CBDR did not reduce overall histologic markers of NAFLD compared with placebo in children. Children receiving CBDR, however, had significant reductions in serum aminotransferase levels and lobular inflammation. ClinicalTrials.gov no: NCT01529268